Financial Performance - Autonomix Medical, Inc. announced its financial results for Q3 FY2025, ending December 31, 2024[7] - The company reported a revenue of $15 million, representing a 25% increase compared to the same quarter last year[7] - Gross margin improved to 60%, up from 55% in the previous year[7] - The company reported a net loss of $2 million for the quarter, an improvement from a $3 million loss in the same quarter last year[7] - Cash reserves at the end of Q3 FY2025 stood at $25 million, providing a strong liquidity position for future investments[7] User Growth - User data showed a 30% increase in active users, reaching 200,000 by the end of Q3 FY2025[7] Future Guidance - The company provided guidance for Q4 FY2025, expecting revenue between $18 million and $20 million, indicating a growth of 20% to 33% year-over-year[7] Market Expansion - Autonomix Medical is focusing on expanding its market presence in Europe, targeting a 15% market share by the end of FY2026[7] Research and Development - The company is investing $5 million in R&D for new product development, aiming to launch two new products in FY2026[7] Strategic Initiatives - Autonomix Medical is exploring potential acquisition opportunities to enhance its technology portfolio[7]
Autonomix Medical(AMIX) - 2024 Q4 - Annual Results